EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study

Lenka Petruzelkova iD, Vit Neuman, Lukas Plachy, Milos Kozak, Barbora Obermannova, Stanislava Kolouskova, Stepanka Pruhova, Zdenek Sumnik

Diabetes Technology & Therapeutics · 2023

DOI: 10.1089/dia.2022.0562 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Lenka Petruzelkova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Insulin, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We evaluated the safety and feasibility of open-source automated insulin delivery AndroidAPS in adolescents and young adults with type 1 diabetes (T1D) and compared its efficacy in three different scenarios: hybrid closed loop (HCL) with meal boluses, meal announcement only (MA), and full closed loop (FCL). Research Design and Methods: In an open-label, prospective, randomized crossover trial ( clinicaltrials.gov NCT04835350), 16 adolescents with T1D (10 females) with mean age of 17 years (range 15–20), glycated hemoglobin 56 mmol/mol (range 43–75), and mean duration of diabetes 5.9 years (9–15) underwent three distinct 3-day periods of camp living, comparing the above-mentioned scenarios of AndroidAPS. We used modified and locked version of AndroidAPS 3.1.03, which was called Pancreas4ALL for study purposes. The order of MA and FCL periods was assigned randomly. The primary endpoints were feasibility and safety of the system represented by percentage of time of glucose control by the system and time in hypoglycemia below 3 mmol/L.

Results

The glycemia was controlled by the system 95% time of the study and the proportion of time below 3 mmol/L did not exceed 1% over the whole study period (0.72%). The HCL scenario reached significantly higher percentage of time below 3 mmol/L (HCL 1.05% vs. MA 0.0% vs. FCL 0.0%; P = 0.05) compared to other scenarios. No difference was observed among the scenarios in the percentage of time between 3.9 and 10 mmol/L (HCL 83.3% vs. MA 79.85% vs. FCL 81.03%, P = 0.58) corresponding to mean glycemia (HCL 6.65 mmol/L vs. MA 7.34 mmol/L vs. FCL 7.05 mmol/L, P = 0.28). No difference was observed in the mean daily dose of insulin or in the daily carbohydrate intake. No serious adverse event occurred during the study period.

Conclusions

Our pilot study showed that FCL might be a realistic mode of treatment for people with T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinDiabetes Mellitus, Type 1FemaleAdolescentYoung AdultHumansAdultHypoglycemic AgentsPilot ProjectsProspective StudiesInsulin Infusion SystemsInsulin, Regular, HumanCross-Over StudiesBlood Glucose

Stichwörter der Autor:innen

Automated insulin deliveryDo-it-yourself systemsFull closed loopHybrid closed loopOpen sourcePancreas4ALL

Substanzen

InsulinHypoglycemic AgentsInsulin, Regular, HumanBlood Glucose

Autor:innen und Institutionen

  • Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
  • IT Department, CLOSED LOOP Systems and Sysop, Prague, Czech Republic.

ORCID-Profile: Lenka Petruzelkova

Zitieren

APA

Petruzelkova, L., Neuman, V., Plachy, L., Kozak, M., Obermannova, B., Kolouskova, S., Pruhova, S., & Sumnik, Z. (2023). First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2022.0562

Vancouver

Petruzelkova L, Neuman V, Plachy L, Kozak M, Obermannova B, Kolouskova S, et al. First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2022.0562

BibTeX
@article{Petruzelkova2023,
  author = {Petruzelkova, Lenka and Neuman, Vit and Plachy, Lukas and Kozak, Milos and Obermannova, Barbora and Kolouskova, Stanislava and Pruhova, Stepanka and Sumnik, Zdenek},
  title = {First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  doi = {10.1089/dia.2022.0562}
}
Kostenlos starten →